[HTML][HTML] Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study
DV Rizk, BH Rovin, H Zhang, N Kashihara… - Kidney international …, 2023 - Elsevier
Introduction Targeting the alternative complement pathway (AP) is an attractive therapeutic
strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology …
strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology …
[HTML][HTML] Quantitative benefit-risk assessment in medical product decision making: a good practices report of an ISPOR task force
T Tervonen, J Veldwijk, K Payne, X Ng, B Levitan… - Value in Health, 2023 - Elsevier
Benefit-risk assessment is commonly conducted by drug and medical device developers
and regulators, to evaluate and communicate issues around benefit-risk balance of medical …
and regulators, to evaluate and communicate issues around benefit-risk balance of medical …
How to integrate evidence from patient preference studies into health technology assessment: a critical review and recommendations
Health technology assessment (HTA) agencies vary in their use of quantitative patient
preference data (PP) and the extent to which they have formalized this use in their …
preference data (PP) and the extent to which they have formalized this use in their …
A discrete choice experiment on oral and injection treatment preferences among moderate‐to‐severe psoriasis patients in Japan
M Komine, H Kim, J Yi, Y Zhong, Y Sakai… - The Journal of …, 2023 - Wiley Online Library
Long‐term psoriasis (PsO) management remains challenging. With growing variation in
treatment efficacy, cost, and modes of administration, patient preferences for different …
treatment efficacy, cost, and modes of administration, patient preferences for different …
Treatment preferences in spinal muscular atrophy: A swing weighting study for caregivers of patients with SMA types 1 and 2
A Patel, W Toro, S Bourke, Y Oluboyede, S Barbier… - Plos one, 2024 - journals.plos.org
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by
skeletal muscle weakness and atrophy. Patients with SMA types 1 and 2 develop severe …
skeletal muscle weakness and atrophy. Patients with SMA types 1 and 2 develop severe …
The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States
J Szklarzewicz, U Floege, D Gallego, K Gibson… - Quality of Life …, 2024 - Springer
Purpose This cross-sectional survey study quantified the humanistic burden of
immunoglobulin A nephropathy (IgAN), in terms of physical and mental health-related …
immunoglobulin A nephropathy (IgAN), in terms of physical and mental health-related …
Clinical and Humanistic Burden of IgA Nephropathy in Adult Patients: A Global Real-World Survey
Background IgA nephropathy (IgAN) is a chronic, progressive kidney disease in which
proteinuria, reduced eGFR, pain, and fatigue are common. How symptoms interact and …
proteinuria, reduced eGFR, pain, and fatigue are common. How symptoms interact and …
Development of a disease-specific health utility score for chronic obstructive pulmonary disease from a discrete choice experiment patient preference study
B Jones, M Ryan, NS Cook… - International Journal of …, 2024 - cambridge.org
ObjectivesWhile patient input to health technology assessment (HTA) has traditionally been
of a qualitative nature, there is increasing interest to integrate quantitative evidence from …
of a qualitative nature, there is increasing interest to integrate quantitative evidence from …
Humanistic and economic burden of IgA nephropathy: systematic literature reviews and narrative synthesis
Abstract Background Immunoglobulin A nephropathy (IgAN) is a progressive inflammatory
kidney disease requiring long-term treatment to reduce the risk of progression to kidney …
kidney disease requiring long-term treatment to reduce the risk of progression to kidney …
Introduction to Patient Preference Studies
B Jones, C Berlin, N Cook, S Dickinson, T Lyu… - … : Clinical Trial Analysis …, 2024 - Springer
This chapter begins with a brief introduction to PFDD (Patient-Focused Drug Development)
and the role a statistician can play in the design and analysis of Patient Preference Studies …
and the role a statistician can play in the design and analysis of Patient Preference Studies …